REG - Poolbeg Pharma PLC - Appointment of Joint Broker

Poolbeg PharmaAnnouncement

30/04/2024 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240430:nRSd4966Ma&default-theme=true

RNS Number : 4966M  Poolbeg Pharma PLC  30 April 2024

Poolbeg Pharma plc

 

Appointment of Joint Broker

 

30 April 2024 - Poolbeg Pharma
(https://url.avanan.click/v2/___http:/www.poolbegpharma.com/___.YXAxZTpzaG9yZWNhcDphOm86YWFlZTUxODZlOWZiNzE1MTQ5NjU2YzYwZjAzNTg0ZmQ6NjphYTNjOmI0NDk5MDgyMzg4N2Y4YmI3NDMyM2ZhYjRmYTQ1Y2FjMTg5NTUzY2EwNDdjMDBhZGY2MTJlYTA3YTY0ODUzZTA6cDpG)
Plc (AIM: POLB, OTCQB: POLBF, 'Poolbeg' or the 'Company'), a
biopharmaceutical company focussed on the development and commercialisation of
innovative medicines targeting diseases with a high unmet medical need, has
appointed Shore Capital Stockbrokers Limited as its Joint Broker with
immediate effect.

 

Cavendish Capital Markets Ltd remains as the Company's Nominated Adviser and
Joint Broker alongside J&E Davy as Joint Broker.

 

Enquiries

 

 Poolbeg Pharma Plc                                                               +44 (0) 207 183 1499

 Jeremy Skillington, CEO

 Ian O'Connell, CFO

 Cavendish Capital Markets Ltd (Nominated Adviser & Joint Broker)                 +44 (0) 207 220 0500

 Geoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward (ECM)

 Shore Capital Stockbrokers Ltd (Joint Broker)                                    +44 (0) 207 408 4090

 David Coaten, Harry Davies-Ball (Corporate Advisory), Malachy McEntyre, Isobel
 Jones (Corporate Broking)

 J&E Davy (Joint Broker)                                                          +353 (0) 1 679 6363

 Anthony Farrell, Niall Gilchrist

 Optimum Strategic Communications                                                 +44 (0) 208 078 4357

 Nick Bastin, Vici Rabbetts, Elena Bates                                          poolbeg@optimumcomms.com (mailto:poolbeg@optimumcomms.com)

 

About Poolbeg Pharma

Poolbeg Pharma plc is committed to the development and commercialisation of
innovative medicines targeting diseases with a high unmet medical need, with a
growing emphasis on rare and orphan diseases. Its model focusses upon
developing its exciting clinical assets and commercialising approved and
marketed drugs to support the growth of the Company and the development of its
robust pipeline of innovative products, thereby driving significant value
creation.

Poolbeg is led by an experienced leadership team with a history of delivering
significant shareholder value. The team has been strengthened by the
appointment of three former members of the Amryt Pharma plc leadership team,
with the intention of repeating Amryt's success and generating near term
revenues.

Poolbeg's clinical programmes target large addressable markets including
cancer immunotherapy-induced CRS, infectious disease, and metabolic conditions
such as obesity with the development of an oral GLP-1R agonist. It uses a
cost-effective development philosophy to generate high quality human data to
support partnering and further development. Its AI-led infectious disease
programmes analyse unique data from human challenge trials to identify
clinically relevant drug targets and treatments, leading to faster development
and greater commercial appeal.

 

For more information, please go to www.poolbegpharma.com
(https://url.avanan.click/v2/___http:/www.poolbegpharma.com/___.YXAxZTpzaG9yZWNhcDphOm86YWFlZTUxODZlOWZiNzE1MTQ5NjU2YzYwZjAzNTg0ZmQ6NjphYTNjOmI0NDk5MDgyMzg4N2Y4YmI3NDMyM2ZhYjRmYTQ1Y2FjMTg5NTUzY2EwNDdjMDBhZGY2MTJlYTA3YTY0ODUzZTA6cDpG)
 or follow us on Twitter
(https://url.avanan.click/v2/___https:/twitter.com/PoolbegPharma___.YXAxZTpzaG9yZWNhcDphOm86YWFlZTUxODZlOWZiNzE1MTQ5NjU2YzYwZjAzNTg0ZmQ6NjoxMTZjOmJjODY0M2RjMzdkZTgxMTdhYzkwNjFiOGRiYjhkYTRmNDdjZjdiN2M0MjIwMTcyOGMxNTliNDM4YTBjYTNjMGM6cDpG)
 and LinkedIn
(https://url.avanan.click/v2/___https:/www.linkedin.com/company/poolbeg-pharma/___.YXAxZTpzaG9yZWNhcDphOm86YWFlZTUxODZlOWZiNzE1MTQ5NjU2YzYwZjAzNTg0ZmQ6Njo2NWE5OjYxYmU2NmQ3YzQ3MDdiNjcwNzQ4NTRiMmRlNTJkYjlhZjJhZTcwMGQ1MzNhYTZhODY0YTc4M2VmMDYyMDEzYWE6cDpG)
 @PoolbegPharma.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPDGGDSCDDDGSC